Recent Updates
Recently added Catalysts
BLCO Positive Sentiment

Bausch + Lomb Announces Publication of Multinational Survey Results Highlighting the Burden of Dry Eye Symptoms and Opportunities for Improved Awareness and Patient Education

Thursday, October 29, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Bausch + Lomb published results from a multinational survey on dry eye symptoms. The survey indicated that self-reported symptoms were more prevalent than diagnoses by healthcare professionals. This highlights a significant gap in awareness and education regarding dry eye among patients and providers.

Market Sentiment Analysis

POSITIVE FACTORS

  • Survey reveals high prevalence of dry eye symptoms.
  • Highlights need for better patient education.
  • Encourages improved awareness among healthcare professionals.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+13%
120-day peak, hindsight
Typical move
1.4%
average across 3 past catalysts
Lead asset
WB007 0.05%
Phase 1 · Glaucoma, Primary Open Angle

Full Press Release Details

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the publication of results from a multinational survey examining symptoms, interactions with health care professionals (HCPs) and treatment experiences to better understand consumer perspectives on dry eye. The findings showed that self-reported dry eye symptoms were more common than reported HCP diagnosis and h

Frequently Asked Questions

What did the Bausch + Lomb survey focus on?

The survey examined dry eye symptoms, healthcare interactions, and treatment experiences.

What was a key finding of the survey?

Self-reported dry eye symptoms were more common than HCP diagnoses.

Why is this survey important?

It highlights the need for improved awareness and education about dry eye.

Who conducted the survey?

The survey was conducted by Bausch + Lomb Corporation.

ShareAdd on Google
Tags: BLCO Bausch + Lomb dry eye healthcare professionals patient education survey results
Last updated: Oct 29, 2026

Biotech snapshot

Cash runway
$513M liquidity · $0M/mo burn
Low dilution risk
Lead asset
WB007 0.05%Phase 1
Glaucoma, Primary Open Angle →

Catalyst track record

+13%
best trade around BLCO's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for BLCO.

See every catalyst's timing & PoA →